Savara (SVRA) Price & Analysis

Compare

1,167 Followers

SVRA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.89 - $4.70

Previous CloseN/A

Volume189.20K

Average Volume (3M)1.19M

Market Cap

$466.66M

Enterprise Value$455.87M

Total Cash (Recent Filing)$172.50M

Total Debt (Recent Filing)$29.64M

Price to Earnings (P/E)―

Beta1.01

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding172,836,930

10 Day Avg. Volume981,643

30 Day Avg. Volume1,188,293

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.98

Enterprise Value/Revenue1.68K

Enterprise Value/Gross Profit6.80K

Enterprise Value/Ebitda-4.18

Forecast

1Y Price Target

$5.50

Price Target Upside103.70% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company expects the current cash runway of $172.5M to last into 2H27, which comfortably surpasses US launch timing.

Market PositionMolbreevi stands to become the first and only approved therapy in the aPAP space, indicating a unique market position.

Regulatory ProgressThe completion of Molbreevi's rolling BLA submission, enabled by Fast Track and Breakthrough Therapy designations, sets up a potential PDUFA in late November or early December.

Bears Say

Investor ConfidenceConcerns arise because Savara management has not conveyed confidence that past mistakes will not be repeated, especially with ongoing dialogue with the FDA.

Regulatory ChallengesThere is added uncertainty and execution concerns due to the Refusal to File letter from the FDA, which could affect the approval process.

Regulatory UncertaintyExamples of other companies facing Refusal to File letters from the FDA suggest potential setbacks and execution challenges ahead.

Savara News

Savara Re-elects Board Members at Annual Meeting

Savara ( ($SVRA) ) has provided an announcement. On June 5, 2025, Savara Inc. held its annual stockholders...

2M ago

SVRA

Savara assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Savara (SVRA) with an Outperform rating with a price target of $5, down from...

2M ago

SVRA

Savara downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Savara (SVRA) to Neutral from Buy with a price target of $2, down from $6,...

2M ago

SVRA

Savara price target lowered to $2 from $3 at Evercore ISI

Evercore ISI lowered the firm’s price target on Savara (SVRA) to $2 from $3 and keeps an In...

2M ago

SVRA

Savara price target lowered to $8 from $9 at Guggenheim

Guggenheim analyst Vamil Divan lowered the firm’s price target on Savara (SVRA) to $8 from $9 and keeps...

2M ago

SVRA

Savara price target lowered to $7 from $8 at Wells Fargo

Wells Fargo lowered the firm’s price target on Savara (SVRA) to $7 from $8 and keeps an Overweight...

2M ago

SVRA

U.S. extends EU tariff deadline, Salesforce to acquire Informatica: Morning Buzz

The major averages were sharply higher near noon following a delay in U.S. tariffs on European Union imports....

2M ago

Savara Faces FDA Setback for MOLBREEVI Application

Savara ( ($SVRA) ) has issued an announcement. On May 27, 2025, Savara Inc. announced it received a...

2M ago

SVRA

Savara receives RTF letter from FDA for Molbreevi BLA

Savara (SVRA) announced that the company received an RTF letter from the FDA for the BLA of Molbreevi...

2M ago

SVRA

Savara announces new data in two poster presentations at ATS Conference 2025

Savara (SVRA) announced new data in two poster presentations at the ATS International Conference 2025. Data presented were...

3M ago

SVRA

Savara’s Strategic Positioning and Financial Strength Drive Buy Rating Amid Anticipated Molbreevi Launch

Savara (SVRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

3M ago

SVRA

Savara price target lowered to $9 from $10 at Citizens JMP

Citizens JMP lowered the firm’s price target on Savara (SVRA) to $9 from $10 and keeps an Outperform...

3M ago

SVRA

Savara reports Q1 EPS (12c), consensus (13c)

As of March 31, 2025, the Company had cash, cash equivalents and short-term investments of ~$172.5 million and...

3M ago

SVRA

Savara’s Strategic Advancements and Market Potential of Molbreevi: A Transformative Approach to aPAP Treatment

Savara (SVRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

4M ago

SVRA

SVRA FAQ

What was Savara’s price range in the past 12 months?

Savara lowest stock price was $1.89 and its highest was $4.70 in the past 12 months.

What is Savara’s market cap?

Savara’s market cap is $466.66M.

When is Savara’s upcoming earnings report date?

Savara’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Savara’s earnings last quarter?

Currently, no data Available

Is Savara overvalued?

According to Wall Street analysts Savara’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Savara pay dividends?

Savara does not currently pay dividends.

What is Savara’s EPS estimate?

Savara’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Savara have?

Savara has 172,836,930 shares outstanding.

What happened to Savara’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Savara?

Currently, no hedge funds are holding shares in SVRA

Savara Stock Smart Score

Underperform

Fundamentals

Return on Equity

-75.77%

Trailing 12-Months

Asset Growth

19.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Savara

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara (SVRA) Earnings & Revenues

Historic Earnings Reports

SVRA Stock 12 Month Forecast

Average Price Target

$5.50

▲(103.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","3.25":"$3.25","5.5":"$5.5","7.75":"$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.25,5.5,7.75,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,3.083076923076923,3.5761538461538462,4.069230769230769,4.562307692307693,5.055384615384615,5.548461538461538,6.041538461538462,6.5346153846153845,7.027692307692307,7.520769230769231,8.013846153846153,8.506923076923076,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,2.813846153846154,3.0376923076923075,3.2615384615384615,3.485384615384615,3.709230769230769,3.933076923076923,4.156923076923077,4.38076923076923,4.604615384615385,4.828461538461538,5.052307692307693,5.276153846153846,{"y":5.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,2.5446153846153843,2.499230769230769,2.4538461538461536,2.4084615384615384,2.363076923076923,2.3176923076923077,2.272307692307692,2.226923076923077,2.1815384615384614,2.1361538461538463,2.0907692307692307,2.0453846153846156,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.95,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.27,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >